The company expressed gratitude to guest speakers, including Bassam Hallis from the UK Health Security Agency, Peter Openshaw from Imperial College London, and Stephen Lockhart, as well as to the hVIVO team and all attendees for their participation in this milestone event.
Looking ahead, hVIVO remains committed to advancing healthcare by driving innovation for the future. The company encourages continued engagement and anticipates sharing more exciting developments from their Canary Wharf unit in the near future.
This event marks a significant step forward for hVIVO in its ongoing mission to revolutionise healthcare.
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
